R R Ghobrial|S M Stepkowski|B D Kahan - JoVE Visualize

Showing results (321-330 of 354) with videos related to

Pageof 36

Sort By:

Transplantation|February 1, 1987

Exacerbation of cyclosporine toxicity by concomitant administration of erythromycinC W Jensen, S M Flechner, C T Van Buren, et al.

Transplantation|February 1, 1991

Chronic rejection in primary renal allograft recipients under cyclosporine-prednisone immunosuppressive therapyR J Knight, R H Kerman, M Welsh, et al.

Transplantation|January 1, 1988

The impact of cytomegalovirus infection on seronegative recipients of seropositive donor kidneys versus seropositive recipients treated with cyclosporine-prednisone immunosuppressionP C Johnson, R M Lewis, D L Golden, et al.

Transplantation|June 15, 1994

Clinical evaluation of induction immunosuppression with a murine IgG2b monoclonal antibody (BMA 031) directed toward the human alpha/beta-T cell receptorR J Knight, R Kurrle, J McClain, et al.

Transplantation|February 1, 1991

Preemptive transplantation--an analysis of benefits and hazards in 85 casesS M Katz, R H Kerman, D Golden, et al.

Transplantation|February 1, 1991

AHG and DTE/AHG procedure identification of crossmatch-appropriate donor-recipient pairings that result in improved graft survivalR H Kerman, P M Kimball, C T Van Buren, et al.

Transplantation|July 1, 1989

Lipid abnormalities in cyclosporine-prednisone-treated renal transplant recipientsA Vathsala, R B Weinberg, L Schoenberg, et al.

Transplantation|February 1, 1989

Stability of renal allograft function associated with long-term cyclosporine immunosuppressive therapy--five year follow-upR M Lewis, R P Janney, D L Golden, et al.

Transplantation Proceedings|April 26, 2005

Transplantation of single pediatric kidneys into adult recipientsZ Csapo, R J Knight, H Podder, et al.

Clinical Pharmacology and Therapeutics|February 17, 2001

Longitudinal assessment of everolimus in de novo renal transplant recipients over the first post-transplant year: pharmacokinetics, exposure-response relationships, and influence on cyclosporineJ M Kovarik, B D Kahan, B Kaplan, et al.

Pageof 36

Showing results (321-330 of 354) with videos related to

Sort By:

Pageof 36

Transplantation|February 1, 1987

Exacerbation of cyclosporine toxicity by concomitant administration of erythromycinC W Jensen, S M Flechner, C T Van Buren, et al.

Transplantation|February 1, 1991

Chronic rejection in primary renal allograft recipients under cyclosporine-prednisone immunosuppressive therapyR J Knight, R H Kerman, M Welsh, et al.

Transplantation|January 1, 1988

The impact of cytomegalovirus infection on seronegative recipients of seropositive donor kidneys versus seropositive recipients treated with cyclosporine-prednisone immunosuppressionP C Johnson, R M Lewis, D L Golden, et al.

Transplantation|June 15, 1994

Clinical evaluation of induction immunosuppression with a murine IgG2b monoclonal antibody (BMA 031) directed toward the human alpha/beta-T cell receptorR J Knight, R Kurrle, J McClain, et al.

Transplantation|February 1, 1991

Preemptive transplantation--an analysis of benefits and hazards in 85 casesS M Katz, R H Kerman, D Golden, et al.

Transplantation|February 1, 1991

AHG and DTE/AHG procedure identification of crossmatch-appropriate donor-recipient pairings that result in improved graft survivalR H Kerman, P M Kimball, C T Van Buren, et al.

Transplantation|July 1, 1989

Lipid abnormalities in cyclosporine-prednisone-treated renal transplant recipientsA Vathsala, R B Weinberg, L Schoenberg, et al.

Transplantation|February 1, 1989

Stability of renal allograft function associated with long-term cyclosporine immunosuppressive therapy--five year follow-upR M Lewis, R P Janney, D L Golden, et al.

Transplantation Proceedings|April 26, 2005

Transplantation of single pediatric kidneys into adult recipientsZ Csapo, R J Knight, H Podder, et al.

Clinical Pharmacology and Therapeutics|February 17, 2001

Longitudinal assessment of everolimus in de novo renal transplant recipients over the first post-transplant year: pharmacokinetics, exposure-response relationships, and influence on cyclosporineJ M Kovarik, B D Kahan, B Kaplan, et al.

Pageof 36